Navigation Links
InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
Date:5/21/2009

BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the clinical feasibility, safety and performance of MGuard when used during Primary PCI in STEMI patients.

The MAGICAL trial is a multicenter, prospective, single arm, 60 patients study (Principal investigator: Dr. Dariusz Dudek, Jagiellonian University, Krakow, Poland). Primary end-points are incidence of complete ST segment resolution measured 60 minutes post procedure and incidence of TIMI 3 flow after PCI. Main secondary endpoints are myocardial blush grade and MACE (major adverse cardiac events) at discharge, 30 days and 6 months.

"I am very pleased and excited we reached this milestone" said Dr. Dariusz Dudek, the MAGICAL Study Chief Investigator, from Jagiellonian University in Krakow. "From the data collected so far, primary PCI for STEMI patients using MGuardTM seems highly safe and effective".

To date, TIMI flow 3 is 91%, MBG 3 (Myocardial Blush Grade) is 74%, Complete ST Resolution is 63%. MACE at discharge is 0% and 30 days MACE to date is 0% as well.

"This important milestone is getting us closer to confirm MGuard's important role in the treatment of acute MI patients, by providing a comprehensive solution to the distal embolization threat" said Eli Bar, CTO and VP R&D at InspireMD. "So far, the MAGICAL Trial results are confirming what we had experienced in cath-labs around the world; that the MGuardTM performs well and delivers extra safety for the patients".

A presentation of the updated results of the MAGICAL trial by Dr. Dariusz Dudek will be given at the InspireMD Cocktail Reception, May 21st at 18:30 at the Hilton Diagonal Mar, next to the EuroPCR conference CCIB Conference center. The Cocktail Reception and Debate: "What is the Best Strategy in Acute M
'/>"/>

SOURCE InspireMD
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
2. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
3. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
4. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
5. Martek to Announce Second Quarter 2009 Results
6. Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil
7. The Hamner Institutes Announce Partnership With China Medical City
8. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
9. Beckman Coulter, Inc. Announces Pricing of Common Stock Offering
10. MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants
11. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...TON, Mass., Dec. 3 Calip... provider of tools and services for drug discovery...ng Image 4.0 software for IVIS® in vivo imagi...than 800 Caliper IVIS systems currently installed ...es advanced spectral unmixing tools to enhance flu...
(Date:12/2/2009)...hilippines, Dec. 2 Spectrum Blue S...en energy companies on the planet. Through the eff...net,s President and Recycling Specialist Leroy Joh...over 25 years, stated that Spectrum Blue Steel is ...tage for spectacular earnings because of the bi pr...
(Date:12/2/2009)...W YORK, Dec. 2 Reportlinker.com an...able in its catalogue: ,, Drug Discovery Techn...pportunities ,, http://www.reportlinker.com/p...ate-of-Market-Trends--Opportunities.html ,, Dr...ement of every pharmaceutical company,s business s...
(Date:12/2/2009)...N, Calif., Dec. 2 Peregr...eported completion of patient enrollment in a dose...in patients with relapsed glioblastoma multiforme ... is a targeted monoclonal antibody linked to a rad...ment for GBM. Cotara specifically targets cells a...
Breaking Biology Technology:Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5
...rsity of Technology (TU/e) have developed an entir...r the first time they used mechanical forces to co...tal concepts in chemistry. This allowed them to in...his discovery paves the way to developing material...nce of mechanical tension. The results of their re...
...er Life Sciences, Inc. (Nasdaq: CALP ) today ann...s will be held on June 2, 2009, at 10:00 a.m. loca...pkinton, Massachusetts. The record date for Calip...s April 16, 2009. , , About Caliper Life Sci...er of cutting-edge technologies enabling researche...
...pril 6 Today, Pepscan reports,that it has achieve...of its,CLIPS-based synthetic peptide immunogen tec...e ligand binding-site on CXCR7 it has induced func... GPCR target CXCR7. CXCR7 is novel,therapeutic tar..., "We are proud and confident with achieving t...
Other Biology Technology:A molecular ripcord for chemical reactions 2Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7 2
(Date:12/2/2009)... study results strengthen the evidence that people...ave an increased risk for developing colorectal ca... , "This provides one more reason not to smoke,...or Michael J. Thun, M.D., M.S., vice president eme...he American Cancer Society. "Colorectal cancer sho...
(Date:12/2/2009)...xposure to secondhand smoke for a prolonged period...k of breast cancer, even in women who never smoked...her exposure to side-stream smoke could increase r...aid Peggy Reynolds, Ph.D., senior research scienti...eley office. "While no single epidemiologic study ...
(Date:12/2/2009)...the University of Georgia College of Veterinary Me...at could open new avenues for treating Ichthyophth...celled protozoan parasite that commonly attacks fr...quencing, researchers found that Ich harbors two a...roides, which are usually found free-living, and R...
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3California Cryobank Introduces Celebrity Look a Likes for Sperm Donors 52899 1California Cryobank Introduces Celebrity Look a Likes for Sperm Donors 52899 2QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 1QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 2QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 3QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 4QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 5QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 6QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 52896 7Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 52892 1Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 52892 2Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 52892 3Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 52892 4Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 52892 5Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 52892 6Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 52892 7Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 52892 8
...et was launched simultaneously by Global Carbon Pr...ris Observatory, and in the USA at Capitol Hill, W... , The Global Carbon Project posted the most recen...understanding the balance of carbon added to the a...te change. Despite the increasing international se...
...h the most commonly performed weight-loss surgery ... developing a rare but serious complication, accor...on of the Journal of Robotic Surgery. , Minimal...dical School at Houston statistically analyzed ope...tions in 605 patients who either underwent laparos...
...y of Colorado at Boulder reveals that air quality ...rce of fine, organic particle pollutants that cont... Los Angeles region. , According to the study, a ...reviously thought is directly emitted by vehicles ...ine, organic particle pollutants form when reactiv...
Other Biology News:Growth in the global carbon budget 2Robotic surgery lowers risk of a rare but serious complication of gastric bypass 2CU-Boulder study suggests air quality regulations miss key pollutants 2
CORNING 1700CM2 ROLLER BOTTLE, EASY GRIP CAP from Sigma-Aldrich
...rescence scanner with 1 or 2 color(s), suitable fo...CGH, ) spotted on standard slides combining perfor...range of InnoScan700 scanners include three differ...ous dual fluorescence scanner (635nm and 532nm). ,...
CORNING ROLLER BOTTLES, 850 CM2, PS, EASY GRIP CAP, STERILE from Sigma-Aldrich
Corning Roller Bottle Easy Grip Caps, Sterile from Sigma-Aldrich
Biology Products: